Logo image of ISRG

INTUITIVE SURGICAL INC (ISRG) Stock Fundamental Analysis

NASDAQ:ISRG - US46120E6023 - Common Stock

466.86 USD
+12.34 (+2.71%)
Last: 9/5/2025, 6:26:49 PM
466.86 USD
0 (0%)
After Hours: 9/5/2025, 6:26:49 PM
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to ISRG. ISRG was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making ISRG a very profitable company, without any liquidiy or solvency issues. ISRG is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, ISRG could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

ISRG had positive earnings in the past year.
ISRG had a positive operating cash flow in the past year.
In the past 5 years ISRG has always been profitable.
ISRG had a positive operating cash flow in each of the past 5 years.
ISRG Yearly Net Income VS EBIT VS OCF VS FCFISRG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

1.2 Ratios

The Return On Assets of ISRG (12.93%) is better than 94.74% of its industry peers.
With an excellent Return On Equity value of 14.52%, ISRG belongs to the best of the industry, outperforming 90.53% of the companies in the same industry.
The Return On Invested Capital of ISRG (13.28%) is better than 93.68% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ISRG is above the industry average of 8.46%.
The 3 year average ROIC (12.20%) for ISRG is below the current ROIC(13.28%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.93%
ROE 14.52%
ROIC 13.28%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ISRG Yearly ROA, ROE, ROICISRG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

ISRG's Profit Margin of 28.51% is amongst the best of the industry. ISRG outperforms 95.79% of its industry peers.
In the last couple of years the Profit Margin of ISRG has declined.
The Operating Margin of ISRG (28.93%) is better than 96.84% of its industry peers.
In the last couple of years the Operating Margin of ISRG has declined.
ISRG has a Gross Margin of 66.61%. This is in the better half of the industry: ISRG outperforms 71.58% of its industry peers.
In the last couple of years the Gross Margin of ISRG has remained more or less at the same level.
Industry RankSector Rank
OM 28.93%
PM (TTM) 28.51%
GM 66.61%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
ISRG Yearly Profit, Operating, Gross MarginsISRG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ISRG is still creating some value.
Compared to 1 year ago, ISRG has more shares outstanding
Compared to 5 years ago, ISRG has more shares outstanding
ISRG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ISRG Yearly Shares OutstandingISRG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ISRG Yearly Total Debt VS Total AssetsISRG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.51
WACC8.81%
ISRG Yearly LT Debt VS Equity VS FCFISRG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

ISRG has a Current Ratio of 5.64. This indicates that ISRG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ISRG (5.64) is better than 80.00% of its industry peers.
A Quick Ratio of 4.89 indicates that ISRG has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.89, ISRG belongs to the best of the industry, outperforming 81.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 4.89
ISRG Yearly Current Assets VS Current LiabilitesISRG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.97% over the past year.
Measured over the past years, ISRG shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.48% on average per year.
The Revenue has grown by 20.77% in the past year. This is a very strong growth!
Measured over the past years, ISRG shows a quite strong growth in Revenue. The Revenue has been growing by 13.27% on average per year.
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%

3.2 Future

Based on estimates for the next years, ISRG will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.53% on average per year.
The Revenue is expected to grow by 14.89% on average over the next years. This is quite good.
EPS Next Y13.56%
EPS Next 2Y13.58%
EPS Next 3Y14.55%
EPS Next 5Y14.53%
Revenue Next Year19.71%
Revenue Next 2Y17.08%
Revenue Next 3Y16.46%
Revenue Next 5Y14.89%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ISRG Yearly Revenue VS EstimatesISRG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
ISRG Yearly EPS VS EstimatesISRG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 58.00, which means the current valuation is very expensive for ISRG.
Based on the Price/Earnings ratio, ISRG is valued a bit cheaper than the industry average as 67.89% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ISRG to the average of the S&P500 Index (27.06), we can say ISRG is valued expensively.
Based on the Price/Forward Earnings ratio of 49.37, the valuation of ISRG can be described as expensive.
ISRG's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ISRG is cheaper than 68.95% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.69, ISRG is valued quite expensively.
Industry RankSector Rank
PE 58
Fwd PE 49.37
ISRG Price Earnings VS Forward Price EarningsISRG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

67.89% of the companies in the same industry are more expensive than ISRG, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ISRG is valued a bit cheaper than the industry average as 71.58% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 83.92
EV/EBITDA 47.63
ISRG Per share dataISRG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ISRG has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ISRG's earnings are expected to grow with 14.55% in the coming years.
PEG (NY)4.28
PEG (5Y)5.05
EPS Next 2Y13.58%
EPS Next 3Y14.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ISRG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTUITIVE SURGICAL INC

NASDAQ:ISRG (9/5/2025, 6:26:49 PM)

After market: 466.86 0 (0%)

466.86

+12.34 (+2.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-22 2025-07-22/amc
Earnings (Next)10-15 2025-10-15/amc
Inst Owners88.73%
Inst Owner Change-5.31%
Ins Owners0.45%
Ins Owner Change-0.78%
Market Cap167.36B
Analysts79
Price Target598.96 (28.3%)
Short Float %1.4%
Short Ratio2.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.33%
Min EPS beat(2)3.05%
Max EPS beat(2)11.61%
EPS beat(4)4
Avg EPS beat(4)11.45%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)8.83%
EPS beat(12)11
Avg EPS beat(12)6.4%
EPS beat(16)13
Avg EPS beat(16)4.58%
Revenue beat(2)2
Avg Revenue beat(2)1.47%
Min Revenue beat(2)1.09%
Max Revenue beat(2)1.84%
Revenue beat(4)3
Avg Revenue beat(4)1.98%
Min Revenue beat(4)-0.14%
Max Revenue beat(4)5.12%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)7
Avg Revenue beat(16)0.13%
PT rev (1m)-0.01%
PT rev (3m)0.88%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)-2.67%
EPS NY rev (1m)4.08%
EPS NY rev (3m)4.34%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.74%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)1.38%
Valuation
Industry RankSector Rank
PE 58
Fwd PE 49.37
P/S 18.3
P/FCF 83.92
P/OCF 59.22
P/B 9.32
P/tB 9.51
EV/EBITDA 47.63
EPS(TTM)8.05
EY1.72%
EPS(NY)9.46
Fwd EY2.03%
FCF(TTM)5.56
FCFY1.19%
OCF(TTM)7.88
OCFY1.69%
SpS25.51
BVpS50.08
TBVpS49.11
PEG (NY)4.28
PEG (5Y)5.05
Profitability
Industry RankSector Rank
ROA 12.93%
ROE 14.52%
ROCE 14.74%
ROIC 13.28%
ROICexc 28.31%
ROICexgc 29.53%
OM 28.93%
PM (TTM) 28.51%
GM 66.61%
FCFM 21.81%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ROICexc(3y)18.44%
ROICexc(5y)19.03%
ROICexgc(3y)19.29%
ROICexgc(5y)20.12%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexcg growth 3Y-7.59%
ROICexcg growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 144.66%
Cap/Sales 9.1%
Interest Coverage 250
Cash Conversion 87.74%
Profit Quality 76.48%
Current Ratio 5.64
Quick Ratio 4.89
Altman-Z N/A
F-Score6
WACC8.81%
ROIC/WACC1.51
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
EPS Next Y13.56%
EPS Next 2Y13.58%
EPS Next 3Y14.55%
EPS Next 5Y14.53%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%
Revenue Next Year19.71%
Revenue Next 2Y17.08%
Revenue Next 3Y16.46%
Revenue Next 5Y14.89%
EBIT growth 1Y34.69%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year40.01%
EBIT Next 3Y23.31%
EBIT Next 5Y20.2%
FCF growth 1Y69.15%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y52.09%
OCF growth 3Y4.95%
OCF growth 5Y8.61%